Spotlight on Gastroenterology

Credits: 1.50 CME
The Changing Landscape of IBD: Emerging Concepts in Patient Management
Raymond K. Cross, MD, MS
Global Education Group

The Changing Landscape of IBD: Emerging Concepts in Patient Management

Start

A Multimedia Educational eHealth Source™

Activity Details

Free CME
1.5 AMA PRA Category 1 Credits
Released: January 17, 2019
Expires: January 17, 2020
1 hour, 30 mins to complete

Jointly Provided by

Target Audience

This activity is intended for clinical gastroenterologists and specialist NP/PAs involved in the treatment of patients with inflammatory bowel disease (IBD).

Learning Objectives

  • Evaluate disease risk and identify individuals who are likely to benefit from biologic or targeted synthetic therapy
  • Tailor management regimens for patients with inflammatory bowel disease (IBD) using a treat-to-target approach that reflects disease severity, treatment goals, therapeutic responses, and patient preferences
  • Partner with patients to provide IBD disease state education, promote shared clinical decision-making, encourage self-management efforts, and personalize long-term care
  • Discuss the cytokine networks underlying IBD pathophysiology, with a focus on newer mechanisms of action
  • Review mechanisms of current and novel non–tumor necrosis factor biologic and targeted synthetic therapies for the treatment of IBD

Activity Description

This activity presents an in-depth review of IBD patient care in moderate to severe disease, including immunopathogenesis of IBD, existing management options, shared decision-making, and investigational targeted therapies, via text and concise video commentaries provided by noted IBD experts

Statement of Educational Need

In the past 2 decades, the introduction of biologic therapies that target underlying disease processes has dramatically changed the treatment of the inflammatory bowel diseases (IBDs)—ulcerative colitis and Crohn’s disease. Current biologic therapy with tumor necrosis factor inhibitors and anti-integrins has improved the treatment of IBD flares and maintenance of clinical remission. These agents are, however, limited by primary nonresponse and loss of response in a substantial proportion of patients, disease relapse after cessation of therapy, immunogenicity, and adverse effects such as risk for infection and malignancy.1 As the pathogenesis and treatment of IBD are complex and variable, there is a need to better understand the underlying pathogenic mechanisms and develop drug therapies to target these mechanisms.1

Geared to the needs of gastroenterologists, this IBD eHealth program includes an update on patient assessment and treat-to-target goals, as well as a review of best practices in shared decision-making in treatment decisions for induction and maintenance of remission. In addition, the immunopathogenesis of IBD is discussed in the context of current and emerging targeted therapies for moderate to severe disease.

Reference

1. Coskun M, Vermeire S, Nielsen OH. Novel targeted therapies for inflammatory bowel disease. Trends Pharmacol Sci. 2017;38(2):127-142.

Agenda

  • Chapter 1: Assessment Strategies and Treatment Goals in IBD
  • Chapter 2: Best Practices in Tailoring Treatment of Moderate and Severe IBD
  • Chapter 3: Evolving Concepts in IBD Pathophysiology
  • Chapter 4: Targeted Mechanism-Based Therapies for IBD on the Horizon

Faculty

Raymond K. Cross, MD, MS
Professor of Medicine
Director, Inflammatory Bowel Disease Program
University of Maryland School of Medicine
Co-Director, Digestive Health Center
University of Maryland Medical Center
Baltimore, MD


Gary R. Lichtenstein, MD
Professor of Medicine
Director, Center for Inflammatory Bowel Diseases
The Raymond and Ruth Perelman School of Medicine of the University of Pennsylvania
Hospital of the University of Pennsylvania
Gastroenterology Division, Department of Internal Medicine
Perelman Center for Advanced Medicine
Philadelphia, PA


Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:


Raymond K. Cross, MD, MS
  • Consultant/Independent Contractor: AbbVie Inc, Janssen, LabCorp, Pfizer, UCB
  • Grant/Research Support: AbbVie Inc

Gary R. Lichtenstein, MD
  • Consultant: AbbVie Inc., Celgene Corporation, Eli Lilly and Company, Ferring Pharmaceuticals Inc., Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc., Luitpold Pharmaceuticals, Inc., Merck & Co., Pfizer Inc., Prometheus Laboratories Inc., Romark, L.C., Salix Pharmaceuticals, Inc., Shire Plc, Takeda Pharmaceuticals North America, Inc., UCB, Inc., Valeant Pharmaceuticals International, Inc.
  • Grant/Research Support: Celgene Corporation, Janssen Pharmaceuticals, Inc., Salix Pharmaceuticals, Inc., Shire Plc, UCB, Inc., Valeant Pharmaceuticals International, Inc.
  • Honoraria: American College of Gastroenterology, Clinical Advances in Gastroenterology, Gastroenterology and Hepatology (Gastro-Hep Communications, Inc.), Luitpold Pharmaceuticals, Inc., McMahon Publishing, Merck & Co., Romark, L.C., Springer Science+Business Media, UpToDate®
  • Other/Royalty: Eli Lilly and Company (Data and Safety Monitoring Board), Janssen Pharmaceuticals, Inc. (Funding for IBD Fellow Education to the University of Pennsylvania), Pfizer Inc. (Funding for IBD Fellow Education to the University of Pennsylvania), SLACK, Incorporated (Book Royalty), Takeda Pharmaceuticals North America, Inc. (Funding for IBD Fellow Education to the University of Pennsylvania)

The planners and managers reported no financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity: Lindsay Borvansky, Andrea Funk, Liddy Knight, Kayla Messer, Jim Kappler, PhD, Julia Muino.

Designation of Credit

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the post-test and program evaluation. Your post-test will automatically be graded. If you successfully complete the post-test (score of 70% or higher), your statement of participation will be made available immediately.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Gastroenterology Presentations

1.00 CME
The Postgraduate Institute for Medicine
IBD In Clinical Practice: Malnutrition Update For Healthcare Providers 2018

IBD In Clinical Practice: Malnutrition Update For Healthcare Providers 2018

Start

Jointly Provided By

This activity is jointly provided by Postgraduate Institute for Medicine, the Crohn's & Colitis Foundation, and RMEI Medical Education, LLC. This activity is supported by an independent medical educational grant from Nestlé Health Science.

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: March 29, 2018
Expires: March 29, 2019
1 hour to complete

Media

Internet

Target Audience

This activity has been designed to meet the educational needs of gastroenterologists and gastroenterology nurse practitioners (NPs) and physician assistants (PAs) who manage patients with IBD.

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  • Summarize the clinical significance of malnutrition and related complications
  • Identify IBD patients who are at risk for malnutrition by using the Malnutrition Universal Screening Tool (MUST)
  • Describe screening, assessment, and intervention/monitoring for malnutrition in IBD patients as outlined by the CCFA IBD Nutrition Care Pathway
  • Engage IBD patients who are at risk or have malnutrition in their healthcare by implementing effective shared decision making strategies

Faculty

Caroline Hwang, MD
Caroline Hwang, MD
Assistant Professor of Clinical Medicine
Medical Director, Inflammatory Bowel Disease Center
Keck/University of Southern California School of Medicine
Los Angeles, CA


Kelly Issokson, MS, RD, CNSC
Kelly Issokson, MS, RD, CNSC
Clinical Dietitian
Cedars-Sinai Medical Center
Los Angeles, CA


Gil Y. Melmed, MD, MS
Gil Y. Melmed, MD, MS
Director of Clinical Inflammatory Bowel Disease (IBD) 
Cedars-Sinai Medical Center
Associate Professor of Medicine
David Geffen University of California, Los Angeles (UCLA) School of Medicine
Los Angeles, CA


Aline Charabaty, MD (Reviewer)
Aline Charabaty, MD (Reviewer)
Associate Professor of Medicine
Director, IBD Center
Medstar Georgetown University Hospital
Washington, DC


Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

  • Caroline Hwang, MD, has affiliations with UCB (Consulting Fees); Janssen, Nestlé Health Science (Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents); AbbVie, Celgene, Eli-Lilly (Contracted Research).
  • Kelly Issokson, MS, RD, CNSC, has no affiliations with commercial interests to disclose.
  • Gil Y. Melmed, MD, MS, has affiliations with AbbVie, Celgene, Janssen, Medtronic, Pfizer, Takeda, UCB (Consulting fees).
  • Aline Charabaty, MD, has affiliations with AbbVie (Consulting Fees); AbbVie, Janssen, Takeda (Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents); Janssen (Contracted Research).

Crohn’s & Colitis Foundation of America

  • Sudha Sarode, MSPH, has no affiliations with commercial interests to disclose.

RMEI Medical Education, LLC

  • Sherri Kramer, MD, has no affiliations with commercial interests to disclose.
  • Faith Reidenbach, CHCP, has no affiliations with commercial interests to disclose.
  • Sharon Powell, has no affiliations with commercial interests to disclose.

Postgraduate Institute for Medicine
The PIM planners and managers, Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP; Judi Smelker-Mitchek, MBA, MSN, RN; and Jan Schultz, MSN, RN, CHCP, have nothing to disclose.

Joint Accreditation Statement

Accreditation Council for Pharmacy Education In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine, the Crohn’s & Colitis Foundation, and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and physician assistants are entitled to receive up to 1.0 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page.
Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.

Physicians, nurse practitioners, and physician assistants who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

Commercial Support

This activity is jointly provided by Postgraduate Institute for Medicine, the Crohn's & Colitis Foundation, and RMEI Medical Education, LLC. This activity is supported by an independent medical educational grant from Nestlé Health Science.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Hardware / Software Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
 
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

1.50 CME
Global Education Group
The Changing Landscape of IBD: Emerging Concepts in Patient Management

The Changing Landscape of IBD: Emerging Concepts in Patient Management

Start

A Multimedia Educational eHealth Source™

Activity Details

Free CME
1.5 AMA PRA Category 1 Credits
Released: January 17, 2019
Expires: January 17, 2020
1 hour, 30 mins to complete

Jointly Provided by

Target Audience

This activity is intended for clinical gastroenterologists and specialist NP/PAs involved in the treatment of patients with inflammatory bowel disease (IBD).

Learning Objectives

  • Evaluate disease risk and identify individuals who are likely to benefit from biologic or targeted synthetic therapy
  • Tailor management regimens for patients with inflammatory bowel disease (IBD) using a treat-to-target approach that reflects disease severity, treatment goals, therapeutic responses, and patient preferences
  • Partner with patients to provide IBD disease state education, promote shared clinical decision-making, encourage self-management efforts, and personalize long-term care
  • Discuss the cytokine networks underlying IBD pathophysiology, with a focus on newer mechanisms of action
  • Review mechanisms of current and novel non–tumor necrosis factor biologic and targeted synthetic therapies for the treatment of IBD

Activity Description

This activity presents an in-depth review of IBD patient care in moderate to severe disease, including immunopathogenesis of IBD, existing management options, shared decision-making, and investigational targeted therapies, via text and concise video commentaries provided by noted IBD experts

Statement of Educational Need

In the past 2 decades, the introduction of biologic therapies that target underlying disease processes has dramatically changed the treatment of the inflammatory bowel diseases (IBDs)—ulcerative colitis and Crohn’s disease. Current biologic therapy with tumor necrosis factor inhibitors and anti-integrins has improved the treatment of IBD flares and maintenance of clinical remission. These agents are, however, limited by primary nonresponse and loss of response in a substantial proportion of patients, disease relapse after cessation of therapy, immunogenicity, and adverse effects such as risk for infection and malignancy.1 As the pathogenesis and treatment of IBD are complex and variable, there is a need to better understand the underlying pathogenic mechanisms and develop drug therapies to target these mechanisms.1

Geared to the needs of gastroenterologists, this IBD eHealth program includes an update on patient assessment and treat-to-target goals, as well as a review of best practices in shared decision-making in treatment decisions for induction and maintenance of remission. In addition, the immunopathogenesis of IBD is discussed in the context of current and emerging targeted therapies for moderate to severe disease.

Reference

1. Coskun M, Vermeire S, Nielsen OH. Novel targeted therapies for inflammatory bowel disease. Trends Pharmacol Sci. 2017;38(2):127-142.

Agenda

  • Chapter 1: Assessment Strategies and Treatment Goals in IBD
  • Chapter 2: Best Practices in Tailoring Treatment of Moderate and Severe IBD
  • Chapter 3: Evolving Concepts in IBD Pathophysiology
  • Chapter 4: Targeted Mechanism-Based Therapies for IBD on the Horizon

Faculty

Raymond K. Cross, MD, MS
Professor of Medicine
Director, Inflammatory Bowel Disease Program
University of Maryland School of Medicine
Co-Director, Digestive Health Center
University of Maryland Medical Center
Baltimore, MD


Gary R. Lichtenstein, MD
Professor of Medicine
Director, Center for Inflammatory Bowel Diseases
The Raymond and Ruth Perelman School of Medicine of the University of Pennsylvania
Hospital of the University of Pennsylvania
Gastroenterology Division, Department of Internal Medicine
Perelman Center for Advanced Medicine
Philadelphia, PA


Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:


Raymond K. Cross, MD, MS
  • Consultant/Independent Contractor: AbbVie Inc, Janssen, LabCorp, Pfizer, UCB
  • Grant/Research Support: AbbVie Inc

Gary R. Lichtenstein, MD
  • Consultant: AbbVie Inc., Celgene Corporation, Eli Lilly and Company, Ferring Pharmaceuticals Inc., Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc., Luitpold Pharmaceuticals, Inc., Merck & Co., Pfizer Inc., Prometheus Laboratories Inc., Romark, L.C., Salix Pharmaceuticals, Inc., Shire Plc, Takeda Pharmaceuticals North America, Inc., UCB, Inc., Valeant Pharmaceuticals International, Inc.
  • Grant/Research Support: Celgene Corporation, Janssen Pharmaceuticals, Inc., Salix Pharmaceuticals, Inc., Shire Plc, UCB, Inc., Valeant Pharmaceuticals International, Inc.
  • Honoraria: American College of Gastroenterology, Clinical Advances in Gastroenterology, Gastroenterology and Hepatology (Gastro-Hep Communications, Inc.), Luitpold Pharmaceuticals, Inc., McMahon Publishing, Merck & Co., Romark, L.C., Springer Science+Business Media, UpToDate®
  • Other/Royalty: Eli Lilly and Company (Data and Safety Monitoring Board), Janssen Pharmaceuticals, Inc. (Funding for IBD Fellow Education to the University of Pennsylvania), Pfizer Inc. (Funding for IBD Fellow Education to the University of Pennsylvania), SLACK, Incorporated (Book Royalty), Takeda Pharmaceuticals North America, Inc. (Funding for IBD Fellow Education to the University of Pennsylvania)

The planners and managers reported no financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity: Lindsay Borvansky, Andrea Funk, Liddy Knight, Kayla Messer, Jim Kappler, PhD, Julia Muino.

Designation of Credit

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the post-test and program evaluation. Your post-test will automatically be graded. If you successfully complete the post-test (score of 70% or higher), your statement of participation will be made available immediately.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.75 CME
American Gastroenterological Association
Optimizing Management in IBD: Challenging Cases

Optimizing Management in IBD: Challenging Cases

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: December 26, 2018
Expires: December 25, 2019
0.75 hour to complete

Accredited By

The American Gastroenterological Association (AGA) Institute

Target Audience

Gastroenterologists and gastroenterology NPs and PAs

Learning Objectives

  • Differentiate between current, novel, and future IBD therapies based on their efficacy and safety data
  • Devise an individualized and adaptable treatment plan for patients with IBD to maximize remission, avoid relapse, and minimize toxicity
  • Assess disease progression and utilize drug monitoring strategies to optimize treatment of patients with IBD
  • Employ a strong patient-provider collaborative approach to managing patients with IBD that includes patient education, engagement, and shared decision making

Faculty

Gil Y. Melmed, MD, MS (Chair)
Co-Director, Clinical Inflammatory Bowel Disease
Division of Gastroenterology/Department of Medicine
Cedars-Sinai Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, CA


Adam S. Cheifetz, MD
Director, Center for Inflammatory Bowel Disease
Beth Israel Deaconess Medical Center
Associate Professor of Medicine
Harvard Medical School
Boston, MA


Gary R. Lichtenstein, MD, FACP, FACG, AGAF
Professor of Medicine
Director, Center for Inflammatory Bowel Diseases
The Raymond and Ruth Perelman School of Medicine of the University of Pennsylvania
Hospital of the University of Pennsylvania
Gastroenterology Division, Department of Internal Medicine
Perelman Center for Advanced Medicine
Philadelphia, PA

Disclosure of Conflicts of Interest

In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

  • Gil Y. Melmed, MD, MS, has affiliations with AbbVie, Janssen, Medtronic, Pfizer, Samsung Bioepis, Takeda (Consulting Fees); Pfizer (Research).
  • Adam S. Cheifetz, MD, has affiliations with AbbVie, Arena, Ferring, Janssen, Pfizer, Samsung, Takeda (Consulting Fees); Miraca (Grant/Research Support).
  • Gary R. Lichtenstein, MD, FACP, FACG, AGAF, has affiliations with Abbott Corporation/AbbVie, Celgene, CellCeutrix, Ferring, Gilead, Janssen Orthobiotech, Luitpold/American Regent, Pfizer Pharmaceuticals, Prometheus Laboratories, Inc., Romark, Salix Pharmaceuticals, Shire, Takeda, UCB (Consulting Fees); Celgene, Janssen Orthobiotech, Salix Pharmaceuticals, Shire, UCB (Research); Luitpold/American Regent, Merck, Romark (Other Financial Benefit).  

RMEI Medical Education, LLC

  • Sherri Kramer, MD, has no affiliations with commercial interests to disclose.
  • Tania Dickson, PhD, has no affiliations with commercial interests to disclose.
  • Sharon Powell, has no affiliations with commercial interests to disclose.

AGA Institute

  • Monique Dyson, has no affiliations with commercial interests to disclose.
  • Sandra Amos, has no affiliations with commercial interests to disclose.

Physician Continuing Medical Education

The American Gastroenterological Association (AGA) Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The AGA Institute designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and PAs are entitled to receive up to 0.75 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.

Physicians, nurse practitioners, and PAs who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. After the successful completion of A Pathway to Evidence-Based Management of IBD and Optimizing Management in IBD: Challenging Cases, learners will receive an AGA-branded certificate recognizing their mastery of IBD management.



COMPLETE THE EVALUATION FORM AND GET A CHANCE TO WIN A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education. No supporter funding was used for the expense of this gift card.
 
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a monthly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your email address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.


Statement of Commercial Support

This activity is supported by independent educational grants from Celgene Corporation, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Salix Pharmaceuticals.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Hardware/Software Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

0.75 CME
American Gastroenterological Association
A Pathway to Evidence-Based Management of IBD

A Pathway to Evidence-Based Management of IBD

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: October 30, 2018
Expires: October 29, 2019
0.75 hour to complete

Accredited By

The American Gastroenterological Association (AGA) Institute

Target Audience

Gastroenterologists and gastroenterology NPs and PAs

Learning Objectives

  • Differentiate between current, novel, and future IBD therapies based on their efficacy and safety data
  • Devise an individualized and adaptable treatment plan for patients with IBD to maximize remission, avoid relapse, and minimize toxicity
  • Assess disease progression and utilize drug monitoring strategies to optimize treatment of patients with IBD
  • Employ a strong patient-provider collaborative approach to managing patients with IBD that includes patient education, engagement, and shared decision making

Faculty

Gil Y. Melmed, MD, MS
Co-Director, Clinical Inflammatory Bowel Disease
Division of Gastroenterology/Department of Medicine
Cedars-Sinai Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, CA

Disclosure of Conflicts of Interest

In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

  • Gil Y. Melmed, MD, MS, has affiliations with AbbVie, Janssen, Medtronic, Pfizer, Samsung Bioepis, Takeda (Consulting Fees).

RMEI Medical Education, LLC

  • Sherri Kramer, MD, has no affiliations with commercial interests to disclose.
  • Tania Dickson, PhD, has no affiliations with commercial interests to disclose.
  • Sharon Powell, has no affiliations with commercial interests to disclose.

AGA Institute

  • Monique Dyson, has no affiliations with commercial interests to disclose.
  • Sandra Amos, has no affiliations with commercial interests to disclose.

Physician Continuing Medical Education

The American Gastroenterological Association (AGA) Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The AGA Institute designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and PAs are entitled to receive up to 0.75 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.

Physicians, nurse practitioners, and PAs who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. After the successful completion of A Pathway to Evidence-Based Management of IBD and Optimizing Management in IBD: Challenging Cases, learners will receive an AGA-branded certificate recognizing their mastery of IBD management.



COMPLETE THE EVALUATION FORM AND GET A CHANCE TO WIN A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education. No supporter funding was used for the expense of this gift card.
 
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a monthly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your email address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.


Statement of Commercial Support

This activity is supported by independent educational grants from Celgene Corporation, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Salix Pharmaceuticals.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Hardware/Software Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.